A Relative Bioavailability Food Effect Study of LY03005

Major Depressive Disorder Clinical Trial

Official title:

A Randomized, Open-Label, 2-Period, Crossover Trial to Assess the Relative Bioavailability of 80 mg LY03005 After Single Dose Administration to Healthy Subjects Under Fed Versus Fasted Conditions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03822065
• Other study ID #: LY03005/CT-USA-105
• Status: Completed
• Phase: Phase 1
• Start date: January 16, 2019
• Est. completion date: February 16, 2019

Study information

• Verified date: January 2019
• Source: Luye Pharma Group Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.

Description:

Thirty-two (32) eligible healthy subjects between ages of 18-50 years old will be enrolled and randomized to either Sequence 1 (fed to fasted state) versus Sequence 2 (fasted to fed state) at a 1:1 ratio.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: February 16, 2019
• Est. primary completion date: February 16, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Capable of giving informed consent and complying with trial procedures;

2. Male and female subjects between the ages of 18 and 50 years, inclusive;

3. Considered healthy by the Investigator based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;

4. Nonsmoker, defined as not having smoked or used any form of tobacco for at least 6 months before Screening based on subject report;

5. Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight >/= 50 kg;

6. Willing and able to adhere to trial procedures and to be confined at the clinical research unit (CRU).

7. All female subjects (childbearing potential and non-childbearing potential) must have a negative serum pregnancy test result at Screening. In addition, female subjects must meet 1 of the following 3 conditions: (a) postmenopausal for at least 12 months without an alternative medical cause, (ii) surgically sterile (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal occlusion) based on subject report, or (iii) if of childbearing potential and heterosexually active, practicing or agree to practice a highly effective method of contraception. Highly effective methods of birth control include an intrauterine device (IUD), intrauterine hormone-releasing system (IUS), and contraceptives (oral, skin patches, or implanted or injectable products) using combined or progestogen-only hormonal contraception associated with inhibition of ovulation. A vasectomized male partner is an acceptable birth control method if the vasectomized partner is the sole sexual partner of the female subject and the vasectomized partner has received medical confirmation of surgical success. Highly effective methods of birth control must be used for at least 14 days prior to study drug dosing, through the end of study (EOS) visit or early termination, and for a minimum of 1 month after the last dose of study drug to minimize the risk of pregnancy. Sexually active, fertile, male subjects must be willing to use acceptable contraception methods (such as double-barrier methods of a combination of male condom with either cap, diaphragm, or sponge with spermicide) from the first dose of study drug through the EOS visit or early termination, and for a minimum of 1 month after the last dose of study drug.

Exclusion Criteria:

1. Clinically significant past medical history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric (including life-long history of depression and/or anxiety), renal, hepatic, bronchopulmonary, neurologic, immunologic, ophthalmological, or lipid metabolism disorders; or drug hypersensitivity; or any condition that in the judgement of the Investigator will affect the trial results or the subject's safety;

2. History of suicide attempt in the past 12 months and/or seen by the Investigator as having a significant history of risk of suicide or homicide;

3. History or presence of malignancy other than adequately treated and cured basal cell skin cancer, squamous cell skin cancer, or in-situ cervical cancer, within 5 years prior to screening;

4. Clinically relevant illness within 1 month prior to Screening or at Screening that may interfere with the conduct of this trial;

5. Medically uncontrolled high blood pressure with mean systolic blood pressure >140 mmHg or mean diastolic blood pressure >90 mmHg at Screening after 3 measurements (after at least 5 minutes of rest in a seated position);

6. History of Long QT Syndrome (LQTS) or a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms);

7. Positive blood screen for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody;

8. History of seizure (history of febrile seizure allowed);

9. Hospital admission or major surgery within 30 days prior to Screening;

10. Participation in any other investigational drug trial within 30 days prior to Screening;

11. History of prescription drug abuse or illicit drug use within 6 months prior to Screening;

12. History of alcohol abuse according to medical history within 6 months prior to Screening;

13. Positive screen for alcohol and/or drugs of abuse;

14. Tobacco use within 6 months prior to Screening based on subject report or positive nicotine screen;

15. History of intolerance or hypersensitivity to ODV or medicines containing ODV or its precursor venlafaxine;

16. Participation in a previous clinical trial of either LY03005 or ODV or medicines containing ODV or its precursor, venlafaxine, within 30 days prior to Screening;

17. Unwillingness or inability to comply with food and beverage restrictions during trial participation;

18. Donation of blood of more than 1 unit (approximate 450 mL) or blood products or acute loss of blood during the 90 days prior to Screening;

19. Use of prescription or over-the-counter (OTC) medications and herbals (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at <3g/day is permitted until 24 hours prior to dosing).

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• LY03005
80 mg oral tablet single dose

Locations

Country	Name	City	State
United States	Pharmaron CPC, Inc.	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Luye Pharma Group Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic Parameters	Area under the concentration-time curve (AUC)	PK samples drawn at predose (within 30 minutes prior to dosing) and at 1, 2, 3, 4 (±5 minutes), 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours (±15 minutes) after the dose.
Primary	Pharmacokinetic Parameters	Maximum concentration (Cmax) for the Pharmacokinetics (PK) of O-desmethyl-venlafaxine (ODV) from LY03005	PK samples drawn at predose (within 30 minutes prior to dosing) and at 1, 2, 3, 4 (±5 minutes), 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours (±15 minutes) after the dose.

External Links

•   Desvenlafaxine
•   Desvenlafaxine Succinate
•   Drug information
•   U.S. FDA Resources